Partridge A - Search Results

1

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.

Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Tolaney SM, et al. Among authors: partridge a. J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2. J Clin Oncol. 2021. PMID: 34077270 Clinical Trial.

2

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Burstein HJ, et al. Among authors: partridge ah. J Clin Oncol. 2001 May 15;19(10):2722-30. doi: 10.1200/JCO.2001.19.10.2722. J Clin Oncol. 2001. PMID: 11352965 Clinical Trial.

3

Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.

Partridge AH, Burstein HJ, Winer EP. Partridge AH, et al. J Natl Cancer Inst Monogr. 2001;(30):135-42. doi: 10.1093/oxfordjournals.jncimonographs.a003451. J Natl Cancer Inst Monogr. 2001. PMID: 11773307 Review.

4

Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years.

Partridge A, Winer E. Partridge A, et al. Clin Breast Cancer. 2000 Jul;1(2):164-5. Clin Breast Cancer. 2000. PMID: 11899655 Review. No abstract available.

5

Treatment of breast cancer during pregnancy.

Burstein HJ, Partridge AH, Lesnikoski BA. Burstein HJ, et al. Expert Opin Pharmacother. 2002 Apr;3(4):423-8. doi: 10.1517/14656566.3.4.423. Expert Opin Pharmacother. 2002. PMID: 11934346 Review.

6

Adherence to therapy with oral antineoplastic agents.

Partridge AH, Avorn J, Wang PS, Winer EP. Partridge AH, et al. J Natl Cancer Inst. 2002 May 1;94(9):652-61. doi: 10.1093/jnci/94.9.652. J Natl Cancer Inst. 2002. PMID: 11983753 Review.

7

Informing clinical trial participants about study results.

Partridge AH, Winer EP. Partridge AH, et al. JAMA. 2002 Jul 17;288(3):363-5. doi: 10.1001/jama.288.3.363. JAMA. 2002. PMID: 12117402 No abstract available.

8

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

Partridge AH, Wang PS, Winer EP, Avorn J. Partridge AH, et al. J Clin Oncol. 2003 Feb 15;21(4):602-6. doi: 10.1200/JCO.2003.07.071. J Clin Oncol. 2003. PMID: 12586795

9

Do patients participating in clinical trials want to know study results?

Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Partridge AH, et al. J Natl Cancer Inst. 2003 Mar 19;95(6):491-2. doi: 10.1093/jnci/95.6.491. J Natl Cancer Inst. 2003. PMID: 12644548 No abstract available.

10

Follow-up care of breast cancer survivors.

Partridge AH, Winer EP, Burstein HJ. Partridge AH, et al. Semin Oncol. 2003 Dec;30(6):817-25. doi: 10.1053/j.seminoncol.2003.08.026. Semin Oncol. 2003. PMID: 14663782

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

580 results

Search Page